Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer

肿瘤穿透微粒治疗胰腺癌的研究

基本信息

项目摘要

The lead investigators at Optimum developed tumor-penetrating microparticles (TPMs), a first-in-class delivery system tailored to the unique anatomical properties of the peritoneal cavity. TPMs are multicomponent, multifunctional, biocompatible, biodegradable, controlled-release polymeric micron-size particles. TPMs are designed to target, penetrate and deliver pharmacodynamically optimized drug levels to the superficial and deep layers of peritoneal tumors. TPMs represent a delivery platform that can be used to deliver small molecule therapeutics, biologics, gene vectors and imaging agents. The first generation TPM, TPM001, is loaded with paclitaxel, with pancreatic cancer as the first indication. The goal is to develop an effective treatment for locoregional control of metastatic pancreatic cancer and, more generally, peritoneal tumors. The BrIDGs team has made progress towards the completion of the following studies on TPM001: - Manufacture of Good Manufacturing Practice (GMP) drug product - Formulation development - Pharmacokinetic/absorption, distribution, metabolism, and excretion (PK/ADME) studies - Investigational New Drug (IND)-directed toxicology
Optimum的主要研究人员开发了肿瘤穿透微粒(TPMs),这是一种针对腹膜腔独特解剖特性量身定制的一流输送系统。TPMs是一种多组分、多功能、生物相容性、可生物降解、控释的微米级聚合物颗粒。TPMs旨在靶向、穿透并将药效学优化的药物水平输送到腹膜肿瘤的浅层和深层。TPMs代表了一个可用于递送小分子治疗药物、生物制剂、基因载体和显像剂的递送平台。第一代TPM TPM001满载紫杉醇,以胰腺癌为第一适应症。目标是开发一种有效的局部控制转移性胰腺癌和腹膜肿瘤的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donald Lo其他文献

Donald Lo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donald Lo', 18)}}的其他基金

Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer
肿瘤穿透微粒治疗胰腺癌的研究
  • 批准号:
    10685882
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
HDAC/PI3K 双重抑制剂治疗罕见癌症
  • 批准号:
    10470638
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
Evaluation of ACT1 to Treat Diabetic Keratopathy
ACT1 治疗糖尿病角膜病的评价
  • 批准号:
    10470634
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2
COVID-19:识别和开发治疗 SARS-CoV-2 的临床候选药物
  • 批准号:
    10686748
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
Helping to End Addiction Long-term (HEAL): Development of Clinical Candidate Drugs for Pain, Addiction and Overdose
帮助长期戒除成瘾 (HEAL):开发治疗疼痛、成瘾和药物过量的临床候选药物
  • 批准号:
    10686744
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
HDAC/PI3K 双重抑制剂治疗罕见癌症
  • 批准号:
    10259368
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2
COVID-19:识别和开发治疗 SARS-CoV-2 的临床候选药物
  • 批准号:
    10259371
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
Development of Nogo Receptor Decoy for the Treatment of Spinal Cord Injury
用于治疗脊髓损伤的 Nogo 受体诱饵的开发
  • 批准号:
    10686732
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
HDAC/PI3K 双重抑制剂治疗罕见癌症
  • 批准号:
    10686743
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:
HEAL: Development of Clinical Candidate Drugs for Pain, Addiction and Overdose
HEAL:开发治疗疼痛、成瘾和药物过量的临床候选药物
  • 批准号:
    10259369
  • 财政年份:
  • 资助金额:
    $ 110.47万
  • 项目类别:

相似海外基金

Disrupted sleep architecture in adolescents with functional abdominal pain disorders
患有功能性腹痛疾病的青少年的睡眠结构被破坏
  • 批准号:
    10641146
  • 财政年份:
    2023
  • 资助金额:
    $ 110.47万
  • 项目类别:
Development and Testing of an Intervention to Facilitate Shared Decision-Making in Pediatric Patients with Abdominal Pain Presenting to the Community Emergency Department Setting
开发和测试一种干预措施,以促进社区急诊科就诊的腹痛儿科患者共同决策
  • 批准号:
    10723374
  • 财政年份:
    2023
  • 资助金额:
    $ 110.47万
  • 项目类别:
Abdominal Pain in Older Patients in Emergency Departments
急诊科老年患者的腹痛
  • 批准号:
    10739136
  • 财政年份:
    2023
  • 资助金额:
    $ 110.47万
  • 项目类别:
Evaluation of abdominal pain after mucosal healing in patients with inflammatory bowel disease -comprehensive analysis of HPA axis-
炎症性肠病患者黏膜愈合后腹痛评价-HPA轴综合分析-
  • 批准号:
    22K16013
  • 财政年份:
    2022
  • 资助金额:
    $ 110.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
  • 批准号:
    10387725
  • 财政年份:
    2022
  • 资助金额:
    $ 110.47万
  • 项目类别:
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
  • 批准号:
    10608073
  • 财政年份:
    2022
  • 资助金额:
    $ 110.47万
  • 项目类别:
Novel microbial driven histamine pathways underlying chronic abdominal pain
慢性腹痛背后的新型微生物驱动组胺途径
  • 批准号:
    453255
  • 财政年份:
    2021
  • 资助金额:
    $ 110.47万
  • 项目类别:
    Operating Grants
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10619029
  • 财政年份:
    2020
  • 资助金额:
    $ 110.47万
  • 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10045379
  • 财政年份:
    2020
  • 资助金额:
    $ 110.47万
  • 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10685484
  • 财政年份:
    2020
  • 资助金额:
    $ 110.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了